Academic Content and Language Evaluation of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (8319)
All Articles published online
|
Publishing Process of This Article
|
Jul 15, 2013 (publication date) through Apr 24, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastrointestinal Oncology
ISSN
1948-5204
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Ramírez-Merino N, Aix SP, Cortés-Funes H. Chemotherapy for cholangiocarcinoma: An update. World J Gastrointest Oncol 2013; 5(7): 171-176 [PMID: 23919111 DOI: 10.4251/wjgo.v5.i7.171] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5204/full/v5/i7/171.htm |
| Number | Citing Articles |
| 1 |
Piya Prajumwongs, Orawan Waenphimai, Kulthida Vaeteewoottacharn, Sopit Wongkham, Kanlayanee Sawanyawisuth. Reversine, a selective MPS1 inhibitor, induced autophagic cell death via diminished glucose uptake and ATP production in cholangiocarcinoma cells. PeerJ 2021; 9: e10637 doi: 10.7717/peerj.10637
|
| 2 |
Peizhan Chen, Bin Li, Yan Zhu, Wei Chen, Xin Liu, Mian Li, Xiaohua Duan, Bin Yi, Jinghan Wang, Chen Liu, Xiangji Luo, Xiaoguang Li, Jingquan Li, Lijian Liang, Xiaoyu Yin, Hui Wang, Xiaoqing Jiang. Establishment and validation of a prognostic nomogram for patients with resectable perihilar cholangiocarcinoma. Oncotarget 2016; 7(24): 37319 doi: 10.18632/oncotarget.9104
|
| 3 |
Amit Kumar Dutta, Umesh Basavaraju, Laura Sales, John Samuel Leeds. Radiofrequency ablation for management of malignant biliary obstruction: a single-center experience and review of the literature. Expert Review of Gastroenterology & Hepatology 2017; 11(8): 779 doi: 10.1080/17474124.2017.1314784
|
| 4 |
Changcan Li, Bao Jin, Hang Sun, Yunchao Wang, Haitao Zhao, Xinting Sang, Huayu Yang, Yilei Mao. Exploring the function of stromal cells in cholangiocarcinoma by three-dimensional bioprinting immune microenvironment model. Frontiers in Immunology 2022; 13 doi: 10.3389/fimmu.2022.941289
|
| 5 |
Andrew X. Zhu, Teresa Macarulla, Milind M. Javle, R. Kate Kelley, Sam J. Lubner, Jorge Adeva, James M. Cleary, Daniel V. T. Catenacci, Mitesh J. Borad, John A. Bridgewater, William P. Harris, Adrian G. Murphy, Do-Youn Oh, Jonathan R. Whisenant, Maeve A. Lowery, Lipika Goyal, Rachna T. Shroff, Anthony B. El-Khoueiry, Christina X. Chamberlain, Elia Aguado-Fraile, Sung Choe, Bin Wu, Hua Liu, Camelia Gliser, Shuchi S. Pandya, Juan W. Valle, Ghassan K. Abou-Alfa. Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation. JAMA Oncology 2021; 7(11): 1669 doi: 10.1001/jamaoncol.2021.3836
|
| 6 |
DONGSHENG XU, YONG MA, BAOLEI ZHAO, SHUAI LI, YU ZHANG, SHANGHA PAN, YAOHUA WU, JIZHOU WANG, DAWEI WANG, HUAYANG PAN, LIANXIN LIU, HONGCHI JIANG. Thymoquinone induces G2/M arrest, inactivates PI3K/Akt and nuclear factor-κB pathways in human cholangiocarcinomas both in vitro and in vivo. Oncology Reports 2014; 31(5): 2063 doi: 10.3892/or.2014.3059
|
| 7 |
Seulki Cho, Tae Sup Lee, In Ho Song, A-Ram Kim, Yoon-Jin Lee, Haejung Kim, Haein Hwang, Mun Sik Jeong, Seung Goo Kang, Hyo Jeong Hong, Aamir Ahmad. Combination of anti-L1 cell adhesion molecule antibody and gemcitabine or cisplatin improves the therapeutic response of intrahepatic cholangiocarcinoma. PLOS ONE 2017; 12(2): e0170078 doi: 10.1371/journal.pone.0170078
|
| 8 |
Chengshuo Zhang, Yu Wang, Gang Wu, Ning Sun, Han Bai, Xuejian Li, Shuai Han, Haonan Zhou, Ruizhao Qi, Jialin Zhang. RPL35A promotes the progression of cholangiocarcinoma by mediating HSPA8 ubiquitination. Biology Direct 2024; 19(1) doi: 10.1186/s13062-024-00453-6
|
| 9 |
Jason Ho, Steven A. Curley. Gastrointestinal Malignancies. Cancer Treatment and Research 2016; : 121 doi: 10.1007/978-3-319-34244-3_7
|
| 10 |
Jean-Florian Guion-Dusserre, Veronique Lorgis, Julie Vincent, Leila Bengrine, Francois Ghiringhelli. FOLFIRI plus bevacizumab as a second-line therapy for metastatic intrahepatic cholangiocarcinoma. World Journal of Gastroenterology 2015; 21(7): 2096-2101 doi: 10.3748/wjg.v21.i7.2096
|
| 11 |
Xiao Zheng, Zhi Yuan Bo, Wei Wan, Ye Chen Wu, Tian Tian Wang, Jun Wu, Dao Jian Gao, Bing Hu. Endoscopic radiofrequency ablation may be preferable in the management of malignant biliary obstruction: A systematic review and meta‐analysis. Journal of Digestive Diseases 2016; 17(11): 716 doi: 10.1111/1751-2980.12429
|
| 12 |
Xiaofang Zhao, Chunyan Zhang, Hong Zhou, Bin Xiao, Ying Cheng, Jinju Wang, Fuli Yao, Chunyan Duan, Run Chen, Youping Liu, Chunhong Feng, Hong Li, Jing Li, Rongyang Dai. Synergistic antitumor activity of the combination of salubrinal and rapamycin against human cholangiocarcinoma cells. Oncotarget 2016; 7(51): 85492 doi: 10.18632/oncotarget.13408
|
| 13 |
Mansi Arora, James M. Bogenberger, Amro Abdelrahman, Jennifer L. Leiting, Xianfeng Chen, Jan B. Egan, Aradhana Kasimsetty, Elzbieta Lenkiewicz, Smriti Malasi, Pedro Luiz Serrano Uson, Bolni Marius Nagalo, Yumei Zhou, Marcela A. Salomao, Heidi E. Kosiorek, Esteban Braggio, Michael T. Barrett, Mark J. Truty, Mitesh J. Borad. Evaluation of NUC-1031: a first-in-class ProTide in biliary tract cancer. Cancer Chemotherapy and Pharmacology 2020; 85(6): 1063 doi: 10.1007/s00280-020-04079-z
|
| 14 |
Manping Huang, Bin Huang, Guowen Li, Sainan Zeng. Apatinib affect VEGF-mediated cell proliferation, migration, invasion via blocking VEGFR2/RAF/MEK/ERK and PI3K/AKT pathways in cholangiocarcinoma cell. BMC Gastroenterology 2018; 18(1) doi: 10.1186/s12876-018-0870-3
|
| 15 |
So Mi Yang, Jueun Kim, Ji-Yeon Lee, Jung-Shin Lee, Ji Min Lee. Regulation of glucose and glutamine metabolism to overcome cisplatin resistance in intrahepatic cholangiocarcinoma. BMB Reports 2023; 56(11): 600 doi: 10.5483/BMBRep.2023-0029
|
| 16 |
Kitti Intuyod, Paula Saavedra-García, Stefania Zona, Chun-Fui Lai, Yannasittha Jiramongkol, Kulthida Vaeteewoottacharn, Chawalit Pairojkul, Shang Yao, Jay-Sze Yong, Sasanan Trakansuebkul, Sakda Waraasawapati, Vor Luvira, Sopit Wongkham, Somchai Pinlaor, Eric W.-F. Lam. RETRACTED ARTICLE: FOXM1 modulates 5-fluorouracil sensitivity in cholangiocarcinoma through thymidylate synthase (TYMS): implications of FOXM1–TYMS axis uncoupling in 5-FU resistance. Cell Death & Disease 2018; 9(12) doi: 10.1038/s41419-018-1235-0
|
| 17 |
Masahito Uji, Takashi Mizuno, Tomoki Ebata, Gen Sugawara, Tsuyoshi Igami, Keisuke Uehara, Masato Nagino. A case of advanced intrahepatic cholangiocarcinoma accidentally, but successfully, treated with capecitabine plus oxaliplatin (CAPOX) therapy combined with bevacizumab: a case report. Surgical Case Reports 2016; 2(1) doi: 10.1186/s40792-016-0191-0
|
| 18 |
Nantana Suwandittakul, Onrapak Reamtong, Pattamaporn Molee, Santi Maneewatchararangsri, Maleerat Sutherat, Urai Chaisri, Sopit Wongkham, Poom Adisakwattana. Disruption of endocytic trafficking protein Rab7 impairs invasiveness of cholangiocarcinoma cells. Cancer Biomarkers 2017; 20(3): 255 doi: 10.3233/CBM-170030
|
| 19 |
Tian Shen, Shanhua Zheng, Lei Geng, Zhengtao Liu, Jun Xu, Bingyi Lin, Junjie Qian, Shusen Zheng. Experience With Anti-PD-1 Antibody, Camrelizumab, Monotherapy for Biliary Tract Cancer Patients and Literature Review. Technology in Cancer Research & Treatment 2020; 19: 153303382097970 doi: 10.1177/1533033820979703
|
| 20 |
Harsha Moole, Sirish Dharmapuri, Abhiram Duvvuri, Sowmya Dharmapuri, Raghuveer Boddireddy, Vishnu Moole, Prathyusha Yedama, Naveen Bondalapati, Achuta Uppu, Charan Yerasi. Endoscopic versus Percutaneous Biliary Drainage in Palliation of Advanced Malignant Hilar Obstruction: A Meta-Analysis and Systematic Review. Canadian Journal of Gastroenterology and Hepatology 2016; 2016: 1 doi: 10.1155/2016/4726078
|
| 21 |
Luca Fabris, Keisaku Sato, Gianfranco Alpini, Mario Strazzabosco. The Tumor Microenvironment in Cholangiocarcinoma Progression. Hepatology 2021; 73(S1): 75 doi: 10.1002/hep.31410
|
| 22 |
Sudarat Sombut, Rada Bunthawong, Uthaiwan Sirion, Teerapich Kasemsuk, Pawinee Piyachaturawat, Kanoknetr Suksen, Apichart Suksamrarn, Rungnapha Saeeng. Synthesis of 14-deoxy-11,12-didehydroandrographolide analogues as potential cytotoxic agents for cholangiocarcinoma. Bioorganic & Medicinal Chemistry Letters 2017; 27(23): 5139 doi: 10.1016/j.bmcl.2017.10.063
|
| 23 |
Gui‐Li Huang, Wei Zhang, Hong‐Yue Ren, Xue‐Ying Shen, Qing‐Xi Chen, Dong‐Yan Shen. Retinoid X receptor α enhances human cholangiocarcinoma growth through simultaneous activation of Wnt/β‐catenin and nuclear factor‐κB pathways. Cancer Science 2015; 106(11): 1515 doi: 10.1111/cas.12802
|
| 24 |
Jose J.G. Marin, Elisa Lozano, Elisa Herraez, Maitane Asensio, Silvia Di Giacomo, Marta R. Romero, Oscar Briz, Maria A. Serrano, Thomas Efferth, Rocio I.R. Macias. Chemoresistance and chemosensitization in cholangiocarcinoma. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2018; 1864(4): 1444 doi: 10.1016/j.bbadis.2017.06.005
|
| 25 |
Yu-Chen S. H. Yang, Hsuen-Wen Chang, I-Hsuan Lin, Li-Nien Chien, Min-Ju Wu, Yun-Ru Liu, Peiguo G. Chu, Guoxiang Xie, Fangcong Dong, Wei Jia, Vincent H. S. Chang, Yun Yen. Long-term Proton Pump Inhibitor Administration Caused Physiological and Microbiota Changes in Rats. Scientific Reports 2020; 10(1) doi: 10.1038/s41598-020-57612-8
|
| 26 |
Laura Fernández, Mikel Gastaca, Eva Alonso, Mikel Prieto, Patricia Ruiz, Alberto Ventoso, Ibone Palomares, Arkaitz Perfecto, Andrés Valdivieso. Surgical treatment for recurrent cholangiocarcinoma: a single-center series. Frontiers in Oncology 2023; 13 doi: 10.3389/fonc.2023.1169133
|
| 27 |
Nathakan Klinhom-on, Wunchana Seubwai, Kanlayanee Sawanyawisuth, Sumalee Obchoei, Panupong Mahalapbutr, Sopit Wongkham. FOXM1 inhibitor, Siomycin A, synergizes and restores 5-FU cytotoxicity in human cholangiocarcinoma cell lines via targeting thymidylate synthase. Life Sciences 2021; 286: 120072 doi: 10.1016/j.lfs.2021.120072
|
| 28 |
Brian C. Brauer. Endotherapy in Biliopancreatic Diseases: ERCP Meets EUS. 2020; : 245 doi: 10.1007/978-3-030-42569-2_22
|
| 29 |
Rafael Caparica, Marco Bruzzone, Georges El Hachem, Marcello Ceppi, Matteo Lambertini, João Glasberg, Evandro de Azambuja, Jean-Luc Van Laethem, Alain Hendlisz. Adjuvant chemotherapy in biliary tract cancer patients: A systematic review and meta-analysis of randomized controlled trials. Critical Reviews in Oncology/Hematology 2020; 149: 102940 doi: 10.1016/j.critrevonc.2020.102940
|
| 30 |
Iago Dillion Lima Cavalcanti. Chemotherapy Protocols and Infusion Sequence. 2022; : 125 doi: 10.1007/978-3-031-10839-6_5
|
| 31 |
Aditya Borakati, Farid Froghi, Ricky H Bhogal, Vasileios K Mavroeidis. Liver transplantation in the management of cholangiocarcinoma: Evolution and contemporary advances. World Journal of Gastroenterology 2023; 29(13): 1969-1981 doi: 10.3748/wjg.v29.i13.1969
|
| 32 |
Michael J Passeri, Maria R Baimas-George, Jesse K Sulzer, David A Iannitti, John B Martinie, Erin H Baker, Lee M Ocuin, Dionisios Vrochides. Prognostic impact of the Bismuth-Corlette classification: Higher rates of local unresectability in stage IIIb hilar cholangiocarcinoma. Hepatobiliary & Pancreatic Diseases International 2020; 19(2): 157 doi: 10.1016/j.hbpd.2020.02.001
|
| 33 |
Laurence Faugeras, Gaetan Cantineau, Jean-Francois Daisne, Thierry Gustin, Lionel D’hondt. Intramedullary spinal cord metastasis of cholangiocarcinoma: a case report. BMC Research Notes 2015; 8(1): 41 doi: 10.1186/s13104-015-0998-y
|
| 34 |
Klaus Mönkemüller, Daniel Popa, C Mel Wilcox. Endoscopic treatment options for cholangiocarcinomas. Expert Review of Anticancer Therapy 2014; 14(4): 407 doi: 10.1586/14737140.2014.870480
|
| 35 |
L'. Laca, I. Dedinská, B. Palkoci, J. Miklušica, J. Janík. Surgical treatment of intrahepatic cholangiocarcinoma: A retrospective cohort study. International Journal of Surgery Open 2016; 4: 10 doi: 10.1016/j.ijso.2016.05.003
|
| 36 |
Elainea N. Smith, Aaron Coleman, Samuel J. Galgano, Constantine M. Burgan, Kristin K. Porter. Oncologic Imaging : a Multidisciplinary Approach. 2023; : 133 doi: 10.1016/B978-0-323-69538-1.00011-2
|
| 37 |
Yaqiong Guo, Pengwei Deng, Wenwen Chen, Zhongyu Li. Modeling Pharmacokinetic Profiles for Assessment of Anti-Cancer Drug on a Microfluidic System. Micromachines 2020; 11(6): 551 doi: 10.3390/mi11060551
|
| 38 |
Keisaku Sato, Heather Francis, Tianhao Zhou, Fanyin Meng, Lindsey Kennedy, Burcin Ekser, Leonardo Baiocchi, Paolo Onori, Romina Mancinelli, Eugenio Gaudio, Antonio Franchitto, Shannon Glaser, Gianfranco Alpini. Neuroendocrine Changes in Cholangiocarcinoma Growth. Cells 2020; 9(2): 436 doi: 10.3390/cells9020436
|
| 39 |
Prin Sungwan, Worachart Lert-itthiporn, Atit Silsirivanit, Nathakan Klinhom-on, Seiji Okada, Sopit Wongkham, Wunchana Seubwai. Bioinformatics analysis identified CDC20 as a potential drug target for cholangiocarcinoma. PeerJ 2021; 9: e11067 doi: 10.7717/peerj.11067
|
| 40 |
Yukihiro Iso, Takatsugu Matsumoto, Yuki Sakuraoka, Takayuki Shiraki, Masato Kato, Mitsugi Shimoda, Taku Aoki, Keiichi Kubota. Preoperative Neutrophil-to-Lymphocyte Ratio for Prognostication of Patients with Distal Bile Duct Carcinomas Undergoing Surgery. Digestive Surgery 2015; 32(2): 142 doi: 10.1159/000380958
|
| 41 |
Asmare Amuamuta, Tullayakorn Plengsuriyakarn, Kesara Na-Bangchang. Anticholangiocarcinoma activity and toxicity of the Kaempferia galanga Linn. Rhizome ethanolic extract. BMC Complementary and Alternative Medicine 2017; 17(1) doi: 10.1186/s12906-017-1713-4
|
| 42 |
Wunchana Seubwai, Kulthida Vaeteewoottacharn, Ratthaphol Kraiklang, Kazuo Umezawa, Seiji Okada, Sopit Wongkham. Inhibition of NF-κB Activity Enhances Sensitivity to Anticancer Drugs in Cholangiocarcinoma Cells. Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics 2016; 23(1): 21 doi: 10.3727/096504015X14424348426071
|
| 43 |
Kuan Wang, Yi-Fong Chen, Yu-Chen S. H. Yang, Haw-Ming Huang, Sheng-Yang Lee, Ya-Jung Shih, Zi-Lin Li, Jacqueline Whang-Peng, Hung-Yun Lin, Paul J. Davis. The power of heteronemin in cancers. Journal of Biomedical Science 2022; 29(1) doi: 10.1186/s12929-022-00816-z
|
| 44 |
Giammaria Fiorentini, Andrea Mambrini, Donatella Sarti, Maurizio Cantore, Luca Mulazzani, Gian Maria Mattioli, Stefano Guadagni. Hepatic intra-arterial and systemic chemotherapy followed by maintenance therapy for the treatment of cholangiocarcinoma. Hepatic Oncology 2017; 4(2): 45 doi: 10.2217/hep-2017-0001
|
| 45 |
Keisaku Sato, Shannon Glaser, Domenico Alvaro, Fanyin Meng, Heather Francis, Gianfranco Alpini. Cholangiocarcinoma: novel therapeutic targets. Expert Opinion on Therapeutic Targets 2020; 24(4): 345 doi: 10.1080/14728222.2020.1733528
|
| 46 |
Yoji Miyahara, Shida Takashi, Yoshiaki Shimizu, Masayuki Ohtsuka. The prognostic impact of neutrophil-to-lymphocyte ratio (NLR) and lymphocyte-to-monocyte ratio (LMR) in patients with distal bile duct cancer. World Journal of Surgical Oncology 2020; 18(1) doi: 10.1186/s12957-020-01847-2
|
| 47 |
E. Una Cidon. Resectable Cholangiocarcinoma: Reviewing the Role of Adjuvant Strategies. Clinical Medicine Insights: Oncology 2016; 10: CMO.S32821 doi: 10.4137/CMO.S32821
|
| 48 |
Arianeb Mehrabi, Mohammad Golriz, Ali Ramouz, Elias Khajeh, Ahmed Hammad, Thilo Hackert, Beat Müller-Stich, Oliver Strobel, Sadeq Ali-Hasan-Al-Saegh, Omid Ghamarnejad, Mohammed Al-Saeedi, Christoph Springfeld, Christian Rupp, Philipp Mayer, Markus Mieth, Benjamin Goeppert, Katrin Hoffmann, Markus W. Büchler. Promising Outcomes of Modified ALPPS for Staged Hepatectomy in Cholangiocarcinoma. Cancers 2023; 15(23): 5613 doi: 10.3390/cancers15235613
|
| 49 |
Kyaw Zwar Myint, Brinda Balasubramanian, Simran Venkatraman, Suchada Phimsen, Supisara Sripramote, Jeranan Jantra, Chaiwat Choeiphuk, Somkit Mingphruedhi, Paramin Muangkaew, Narongsak Rungsakulkij, Pongsatorn Tangtawee, Wikran Suragul, Watoo Vassanasiri Farquharson, Kanokpan Wongprasert, Somchai Chutipongtanate, Pimtip Sanvarinda, Marisa Ponpuak, Naravat Poungvarin, Tavan Janvilisri, Tuangporn Suthiphongchai, Kiren Yacqub-Usman, Anna M. Grabowska, David O. Bates, Rutaiwan Tohtong. Therapeutic Implications of Ceritinib in Cholangiocarcinoma beyond ALK Expression and Mutation. Pharmaceuticals 2024; 17(2): 197 doi: 10.3390/ph17020197
|
| 50 |
Shaoyi Chen, Zuxiao Chen, Zongyan Li, Shiying Li, Zilong Wen, Liangqi Cao, Yubin Chen, Ping Xue, Haiyan Li, Dawei Zhang. Tumor-associated macrophages promote cholangiocarcinoma progression via exosomal Circ_0020256. Cell Death & Disease 2022; 13(1) doi: 10.1038/s41419-022-04534-0
|
| 51 |
Daljeet Chahal, Chris Shamatutu, Bill Salh, Janine Davies. The impact of primary sclerosing cholangitis or inflammatory bowel disease on cholangiocarcinoma phenotype, therapy, and survival. JGH Open 2020; 4(6): 1128 doi: 10.1002/jgh3.12405
|
| 52 |
Pyung Jung, Eung-Ho Cho, Sang-Bum Kim, Ryoung-Go Kim. Comparison of the clinical results of surgical resection for extrahepatic cholangiocarcinomas: Hilar cholangiocarcinoma and mid-to-distal cholangiocarcinoma. Annals of Hepato-Biliary-Pancreatic Surgery 2019; 23(4): 319 doi: 10.14701/ahbps.2019.23.4.319
|
| 53 |
Hong Peng, Qiuyang Zhang, Jiali Li, Ning Zhang, Yunpeng Hua, Lixia Xu, Yubin Deng, Jiaming Lai, Zhenwei Peng, Baogang Peng, Minhu Chen, Sui Peng, Ming Kuang. Apatinib inhibits VEGF signaling and promotes apoptosis in intrahepatic cholangiocarcinoma. Oncotarget 2016; 7(13): 17220 doi: 10.18632/oncotarget.7948
|
| 54 |
Ye-Yu Zhao, Si-Hai Chen, Qin-Si Wan. A prognostic nomogram for distal bile duct cancer from Surveillance, Epidemiology, and End Results (SEER) database based on the STROBE compliant. Medicine 2019; 98(46): e17903 doi: 10.1097/MD.0000000000017903
|
| 55 |
Sihem Sebbagh, Julia Roux, Chantal Dreyer, Cindy Neuzillet, Armand de Gramont, Cecilia Orbegoso, Olivia Hentic, Pascal Hammel, Aimery de Gramont, Eric Raymond, Thierry André, Benoist Chibaudel, Sandrine Faivre. Efficacy of a sequential treatment strategy with GEMOX-based followed by FOLFIRI-based chemotherapy in advanced biliary tract cancers. Acta Oncologica 2016; 55(9-10): 1168 doi: 10.1080/0284186X.2016.1191670
|
| 56 |
Yoshihiro Miyazaki, Takashi Kokudo, Katsumi Amikura, Yumiko Kageyama, Amane Takahashi, Nobuhiro Ohkohchi, Hirohiko Sakamoto. Survival of surgery for recurrent biliary tract cancer: a single-center experience and systematic review of literature. Japanese Journal of Clinical Oncology 2017; 47(3): 206 doi: 10.1093/jjco/hyw182
|
| 57 |
Maeve A Lowery, Howard A Burris, Filip Janku, Rachna T Shroff, James M Cleary, Nilofer S Azad, Lipika Goyal, Elizabeth A Maher, Lia Gore, Antoine Hollebecque, Muralidhar Beeram, Jonathan C Trent, Liewen Jiang, Bin Fan, Elia Aguado-Fraile, Sung Choe, Bin Wu, Camelia Gliser, Samuel V Agresta, Shuchi S Pandya, Andrew X Zhu, Ghassan K Abou-Alfa. Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study. The Lancet Gastroenterology & Hepatology 2019; 4(9): 711 doi: 10.1016/S2468-1253(19)30189-X
|
| 58 |
Mai Ly Thi Nguyen, Khac Cuong Bui, Tim Scholta, Jun Xing, Vikas Bhuria, Bence Sipos, Ludwig Wilkens, Toan Nguyen Linh, Thirumalaisamy P Velavan, Przemyslaw Bozko, Ruben R Plentz. Targeting interleukin 6 signaling by monoclonal antibody siltuximab on cholangiocarcinoma. Journal of Gastroenterology and Hepatology 2021; 36(5): 1334 doi: 10.1111/jgh.15307
|
| 59 |
S. O’Brien, N. Bhutiani, M. E. Egger, A. N. Brown, K. H. Weaver, D. Kline, L. R. Kelly, C. R. Scoggins, R. C. G. Martin, G. C. Vitale. Comparing the efficacy of initial percutaneous transhepatic biliary drainage and endoscopic retrograde cholangiopancreatography with stenting for relief of biliary obstruction in unresectable cholangiocarcinoma. Surgical Endoscopy 2020; 34(3): 1186 doi: 10.1007/s00464-019-06871-2
|
| 60 |
In Ho Song, Mun Sik Jeong, Hyo Jeong Hong, Jong Il Shin, Yong Serk Park, Sang-Keun Woo, Byung Seok Moon, Kwang Il Kim, Yong Jin Lee, Joo Hyun Kang, Tae Sup Lee. Development of a Theranostic Convergence Bioradiopharmaceutical for Immuno-PET Based Radioimmunotherapy of L1CAM in Cholangiocarcinoma Model. Clinical Cancer Research 2019; 25(20): 6148 doi: 10.1158/1078-0432.CCR-19-1157
|
| 61 |
Alexander R. Siebenhüner, Heike Seifert, Helga Bachmann, Burkhardt Seifert, Thomas Winder, Jonas Feilchenfeldt, Stefan Breitenstein, Pierre-Alain Clavien, Roger Stupp, Alexander Knuth, Bernhard Pestalozzi, Panagiotis Samaras. Adjuvant treatment of resectable biliary tract cancer with cisplatin plus gemcitabine: A prospective single center phase II study. BMC Cancer 2018; 18(1) doi: 10.1186/s12885-017-3967-0
|
| 62 |
Jie Deng, Li Liu, Li Li, Jianhai Sun, Fei Yan. Hesperidin delays cell cycle progression into the G0/G1 phase via suspension of MAPK signaling pathway in intrahepatic cholangiocarcinoma. Journal of Biochemical and Molecular Toxicology 2022; 36(4) doi: 10.1002/jbt.22981
|
| 63 |
Su Jin Kim, Suyeon Jun, Hee-Yeon Cho, Dong Chul Lee, Young Il Yeom, Jong Hyeok Kim, Dongchul Kang. Knockdown of anterior gradient 2 expression extenuates tumor-associated phenotypes of SNU-478 ampulla of Vater cancer cells. BMC Cancer 2014; 14(1) doi: 10.1186/1471-2407-14-804
|
| 64 |
Mahesh Kr Goenka, Usha Goenka. Palliation: Hilar cholangiocarcinoma. World Journal of Hepatology 2014; 6(8): 559-569 doi: 10.4254/wjh.v6.i8.559
|
| 65 |
Ahmed O. Kaseb, Marc Uemura, Melanie B. Thomas, Steven A. Curley. Holland‐Frei Cancer Medicine. 2017; : 1 doi: 10.1002/9781119000822.hfcm093
|
| 66 |
Thidarath Rattanaburee, Patpanat Sermmai, Kornthip Tangthana-umrung, Tienthong Thongpanchang, Potchanapond Graidist. Anticancer Activity of (±)-Kusunokinin Derivatives towards Cholangiocarcinoma Cells. Molecules 2022; 27(23): 8291 doi: 10.3390/molecules27238291
|
| 67 |
Bundit Promraksa, Praewpan Katrun, Jutarop Phetcharaburanin, Yingpinyapat Kittirat, Nisana Namwat, Anchalee Techasen, Jia V. Li, Watcharin Loilome. Metabolic Changes of Cholangiocarcinoma Cells in Response to Coniferyl Alcohol Treatment. Biomolecules 2021; 11(3): 476 doi: 10.3390/biom11030476
|
| 68 |
Yang Zou, Rong Li, Dabin Kuang, Meiling Zuo, Wenqun Li, Wei Tong, Li Jiang, Min Zhou, Yin Chen, Wencheng Gong, Lijuan Liu, Fangfang Tou. Galangin Inhibits Cholangiocarcinoma Cell Growth and Metastasis through Downregulation of MicroRNA-21 Expression. BioMed Research International 2020; 2020: 1 doi: 10.1155/2020/5846938
|
| 69 |
ARUNEE HEMATULIN, DANIEL SAGAN, KANLAYANEE SAWANYAWISUTH, WUNCHANA SEUBWAI, SOPIT WONGKHAM. Association between cellular radiosensitivity and G1/G2 checkpoint proficiencies in human cholangiocarcinoma cell lines. International Journal of Oncology 2014; 45(3): 1159 doi: 10.3892/ijo.2014.2520
|
| 70 |
Luca Filippi, Giovan Giuseppe Di Costanzo, Raffaella Tortora, Giuseppe Pelle, Roberto Cianni, Orazio Schillaci, Oreste Bagni. Repeated Treatment with 90Y-Microspheres in Intrahepatic Cholangiocarcinoma Relapsed After the First Radioembolization. Cancer Biotherapy and Radiopharmaceuticals 2019; 34(4): 231 doi: 10.1089/cbr.2018.2718
|
| 71 |
Koushik Sarker , Avijit Ghosh , Abhijit Saha, Suvasish Mishra, Subrata Sen. Pharmacophore Based Design of Probable FGFR-1 Inhibitors from the 3D
Crystal Structure of Infigratinib - A Drug Used in the Treatment of
Cholangiocarcinomas. Letters in Drug Design & Discovery 2022; 19(4): 314 doi: 10.2174/1570180818666211007113720
|
| 72 |
Kathryn White, Ahmed I Anwar, Kevin Jin, Victoria Bollich, Rucha A Kelkar, Norris C Talbot, Rachel J Klapper, Shahab Ahmadzadeh, Omar Viswanath, Giustino Varrassi, Sahar Shekoohi, Alan D Kaye. Infigratinib for the Treatment of Metastatic or Locally Advanced Cholangiocarcinoma With Known FGFR2 Gene Fusions or Rearrangements. Cureus 2023; doi: 10.7759/cureus.46792
|
| 73 |
Reem Z. Sharaiha, Amrita Sethi, Kristen R. Weaver, Tamas A. Gonda, Raj J. Shah, Norio Fukami, Prashant Kedia, Nikhil A. Kumta, Carlos M. Rondon Clavo, Michael D. Saunders, Jorge Cerecedo-Rodriguez, Paola Figueroa Barojas, Jessica L. Widmer, Monica Gaidhane, William R. Brugge, Michel Kahaleh. Impact of Radiofrequency Ablation on Malignant Biliary Strictures: Results of a Collaborative Registry. Digestive Diseases and Sciences 2015; 60(7): 2164 doi: 10.1007/s10620-015-3558-3
|
| 74 |
Giovanni Brandi, Michela Venturi, Maria Abbondanza Pantaleo, Giorgio Ercolani, Lorenzo Fornaro, Nicola Silvestris, Francesco Leone, Enrico Vasile, Sara Lonardi, Stefano Cereda, Daniele Santini, Giuseppe Aprile. Cholangiocarcinoma: Current opinion on clinical practice diagnostic and therapeutic algorithms. Digestive and Liver Disease 2016; 48(3): 231 doi: 10.1016/j.dld.2015.11.017
|
| 75 |
Jinyang Gu, Lei Xia, Biyun Xu, Tianfei Lu, Obulkasim Halmurat, Jun Wang, Jianjun Zhang, Yitao Ding, Qiang Xia. Clinical prognostic significance of regional and extended lymphadenectomy for biliary cancer with para-aortic lymph node metastasis: A systematic review and meta-analysis. Digestive and Liver Disease 2016; 48(7): 717 doi: 10.1016/j.dld.2016.03.019
|
| 76 |
Kotoe Takayoshi, Kosuke Sagara, Keita Uchino, Hitoshi Kusaba, Naotaka Sakamoto, Atsushi Iguchi, Eishi Baba. A case of metastatic renal cell carcinoma and bile duct carcinoma treated with a combination of sunitinib and gemcitabine. BMC Cancer 2015; 15(1) doi: 10.1186/s12885-015-1443-2
|
| 77 |
Uttapol Permpoon, Fatima Khan, Sri Murugan Poonkavithai Vadevoo, Smriti Gurung, Gowri Rangaswamy Gunassekaran, Min-Jong Kim, Sang-Hyun Kim, Peti Thuwajit, Byungheon Lee. Inhibition of Tumor Growth against Chemoresistant Cholangiocarcinoma by a Proapoptotic Peptide Targeting Interleukin-4 Receptor. Molecular Pharmaceutics 2020; 17(11): 4077 doi: 10.1021/acs.molpharmaceut.0c00529
|
| 78 |
Gahyun Gim, Nabeel Badri. Challenges and opportunities for treating intrahepatic cholangiocarcinoma: targeted therapy. Hepatoma Research 2023; doi: 10.20517/2394-5079.2023.90
|
| 79 |
Samuel C. Fehling, Aubrey L. Miller, Patrick L. Garcia, Rebecca B. Vance, Karina J. Yoon. The combination of BET and PARP inhibitors is synergistic in models of cholangiocarcinoma. Cancer Letters 2020; 468: 48 doi: 10.1016/j.canlet.2019.10.011
|
| 80 |
Zhong-Ming Wu, Li Wang, Wei Zhu, Ying-Hua Gao, Hai-Ming Wu, Mi Wang, Tai-Shan Hu, Yi-Jia Yan, Zhi-Long Chen. Preparation of a chlorophyll derivative and investigation of its photodynamic activities against cholangiocarcinoma. Biomedicine & Pharmacotherapy 2017; 92: 285 doi: 10.1016/j.biopha.2017.05.052
|
| 81 |
Shogo Kobayashi, Hiroaki Nagano, Daisuke Sakai, Hidetoshi Eguchi, Etsuro Hatano, Masashi Kanai, Satoru Seo, Kojiro Taura, Yutaka Fujiwara, Tetsuo Ajiki, Shigekazu Takemura, Shoji Kubo, Hiroaki Yanagimoto, Hideyoshi Toyokawa, Akihito Tsuji, Hiroaki Terajima, Satoshi Morita, Tatsuya Ioka. Phase I study of adjuvant gemcitabine or S-1 in patients with biliary tract cancers undergoing major hepatectomy: KHBO1003 study. Cancer Chemotherapy and Pharmacology 2014; 74(4): 699 doi: 10.1007/s00280-014-2543-4
|
| 82 |
Pathanin Chantree, Sirilak Chumkiew, Mantana Jamklang, Pongsakorn Martviset. Cytotoxic activities of ethanolic crude extracts from fruiting bodies of bamboo mushrooms (Dictyophora spp.) against cholangiocarcinoma cells. Research Results in Pharmacology 2022; 8(1): 33 doi: 10.3897/rrpharmacology.8.72098
|
| 83 |
Nanmu Yang, Feng Han, Hong Cui, Jinxi Huang, Tao Wang, Yi Zhou, Jinxue Zhou. Matrine suppresses proliferation and induces apoptosis in human cholangiocarcinoma cells through suppression of JAK2/STAT3 signaling. Pharmacological Reports 2015; 67(2): 388 doi: 10.1016/j.pharep.2014.10.016
|
| 84 |
Yu Takahashi, Tomoki Ebata, Yukihiro Yokoyama, Tsuyoshi Igami, Gen Sugawara, Takashi Mizuno, Yuji Nimura, Masato Nagino. Surgery for Recurrent Biliary Tract Cancer. Annals of Surgery 2015; 262(1): 121 doi: 10.1097/SLA.0000000000000827
|
| 85 |
Takahiro Tsuchikawa, Satoshi Hirano, Keisuke Okamura, Joe Matsumoto, Eiji Tamoto, Soichi Murakami, Toru Nakamura, Yuma Ebihara, Yo Kurashima, Toshiaki Shichinohe. Advances in the surgical treatment of hilar cholangiocarcinoma. Expert Review of Gastroenterology & Hepatology 2015; 9(3): 369 doi: 10.1586/17474124.2015.960393
|
| 86 |
Renuka V. Iyer, Venkata K. Pokuri, Adrienne Groman, Wen W. Ma, Usha Malhotra, Dan M. Iancu, Catherine Grande, Tanios B. Saab. A Multicenter Phase II Study of Gemcitabine, Capecitabine, and Bevacizumab for Locally Advanced or Metastatic Biliary Tract Cancer. American Journal of Clinical Oncology 2018; 41(7): 649 doi: 10.1097/COC.0000000000000347
|
| 87 |
Haejung Kim, Haein Hwang, Hansoo Lee, Hyo Jeong Hong. L1 Cell Adhesion Molecule Promotes Migration and Invasion via JNK Activation in Extrahepatic Cholangiocarcinoma Cells with Activating KRAS Mutation. Molecules and Cells 2017; 40(5): 363 doi: 10.14348/molcells.2017.2282
|
| 88 |
Wei-Wen Chang, Ping-Kun Hsiao, Lei Qin, Chia-Lun Chang, Jyh-Ming Chow, Szu-Yuan Wu. Treatment outcomes for unresectable intrahepatic cholangiocarcinoma: Nationwide, population-based, cohort study based on propensity score matching with the Mahalanobis metric. Radiotherapy and Oncology 2018; 129(2): 284 doi: 10.1016/j.radonc.2018.09.010
|
| 89 |
Huijie Gao, Zhaobin He, Chao Gao, Naiqing Liu, Zhaoyang Zhang, Weibo Niu, Jun Niu, Cheng Peng. Exosome-transmitted miR-3124-5p promotes cholangiocarcinoma development via targeting GDF11. Frontiers in Oncology 2022; 12 doi: 10.3389/fonc.2022.936507
|
| 90 |
T. Hauge, P.W. Hauge, T. Warloe, A. Drolsum, C. Johansen, E. Viktil, L. Aabakken, T. Buanes, Z. Konopski. Randomised controlled trial of temoporfin photodynamic therapy plus chemotherapy in nonresectable biliary carcinoma—PCS Nordic study. Photodiagnosis and Photodynamic Therapy 2016; 13: 330 doi: 10.1016/j.pdpdt.2015.09.004
|
| 91 |
Brinda Balasubramanian, Simran Venkatraman, Kyaw Zwar Myint, Sucheewin Krobthong, Patompon Wongtrakoongate, Jittiyawadee Sripa, Panthip Rattanasinganchan, Pornphimon Metheenukul, Rutaiwan Tohtong. In Silico Target Identification of Galangin, as an Herbal Flavonoid against Cholangiocarcinoma. Molecules 2022; 27(14): 4664 doi: 10.3390/molecules27144664
|
| 92 |
Yaoting Chen, Huiqing Li, Xiongying Jiang, Dong Chen, Jiayan Ni, Hongliang Sun, Jianghong Luo, Herui Yao, Linfeng Xu. Regional thermochemotherapy versus hepatic arterial infusion chemotherapy for palliative treatment of advanced hilar cholangiocarcinoma: a retrospective controlled study. European Radiology 2016; 26(10): 3500 doi: 10.1007/s00330-016-4208-7
|
| 93 |
Dawn Q. Chong, Andrew X. Zhu. The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets. Oncotarget 2016; 7(29): 46750 doi: 10.18632/oncotarget.8775
|